ENSPRYNG
for NMOSD in AQP4-IgG(+) adults

Helping you understand treatment with ENSPRYNG

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

What is ENSPRYNG?

ENSPRYNG is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. It is not known if ENSPRYNG is safe and effective in children.

Who should not receive ENSPRYNG?

Do not take ENSPRYNG if you:

- are allergic to ENSPRYNG or any of the ingredients in ENSPRYNG.
- have an active hepatitis B infection.
- have active or untreated inactive (latent) tuberculosis.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

What Is ENSPRYNG?

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

What is ENSPRYNG?

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

Who can take ENSPRYNG?

ENSPRYNG is approved for neuromyelitis optica spectrum disorder (NMOSD) in AQP4-IgG(+) adults.

How ENSPRYNG is thought to work

The specific way ENSPRYNG works is not completely understood, but it is thought to affect the protein interleukin-6 (IL-6).

ENSPRYNG is the first treatment for NMOSD designed to block IL-6, a protein made by immune cells in our bodies that may play a key role in the inflammation that occurs in people with NMOSD.

Important Safety Information

What is the most important information I should know about ENSPRYNG?

ENSPRYNG may cause serious side effects including:

- **Infections.** ENSPRYNG can increase your risk of serious infections some of which can be life-threatening. Talk to your healthcare provider if you are being treated for an infection or call them right away if you think you have signs of an infection, with or without a fever, such as:

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

What is ENSPRYNG?

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

ENSPRYNG is designed to block the action of a protein in your body called IL-6, which is believed to play a part in NMOSD.



Without ENSPRYNG

IL-6 connects to the cell surface and activates the cell.



With ENSPRYNG

ENSPRYNG blocks IL-6 from connecting to the cell surface and prevents the activation of the cell.

Important Safety Information

- chills, feeling tired, muscle aches, cough that will not go away or a sore throat
- skin redness, swelling, tenderness, pain or sores on your body
- diarrhea, belly pain, or feeling sick
- burning when you urinate or urinating more often than usual

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

ENSPRYNG Clinical Trial Results

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

What is ENSPRYNG?

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

A clinical trial tests how well a medical treatment works in people and can determine whether a new treatment is beneficial and safe.

What were the goals of the ENSPRYNG clinical trials?

Two clinical trials were conducted to determine whether ENSPRYNG alone or ENSPRYNG in combination with immunosuppressive therapy (IST) could lower the risk of relapse in adults with NMOSD vs. placebo. These ISTs include azathioprine, mycophenolate mofetil, and/or oral corticosteroids. Both trials also measured how many patients were relapse-free at specific time points with treatment.

Important Safety Information

Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take ENSPRYNG.

- Your healthcare provider should test you for hepatitis and tuberculosis (TB) before you start taking ENSPRYNG.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

What is ENSPRYNG?

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

How was ENSPRYNG studied?

Patients from countries around the world participated in the two trials

A wide range of patients in terms of age, gender, AQP4-IgG status, and severity of disease were represented in the clinical trials:

- Men and women, with a larger proportion of women
- Patients who were AQP4-IgG(+) or AQP4-IgG(–)
- Patients with at least one confirmed relapse over the past year

Study 1 excluded patients who were recently taking other treatments before starting the trial

Study 2 only included patients who were taking certain ISTs (azathioprine, mycophenolate mofetil, or oral corticosteroids) before starting the trial

ENSPRYNG is only approved for AQP4-IgG(+) adults

Important Safety Information

- All required vaccinations should be completed before starting ENSPRYNG. People using ENSPRYNG should not be given 'live' or 'live-attenuated' vaccines. 'Live' or 'live-attenuated' vaccines should be given at least 4 weeks before you start ENSPRYNG. Your healthcare provider may recommend that you get a 'non-live' (inactivated) vaccine, such as some of the seasonal flu vaccines. If you plan to get a 'non-live' (inactivated) vaccine it should be given, whenever possible, at least 2 weeks before you start ENSPRYNG.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Study 1: ENSPRYNG vs placebo

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

Overview of Study 1



Important Safety Information

- **Increased liver enzymes.**
  Your healthcare provider should order blood tests to check your liver enzymes before and while you are taking ENSPRYNG. Your healthcare provider will tell you how often you will need to have these blood tests. Make sure you get all of your follow-up blood tests as ordered by your healthcare provider. Your healthcare provider will tell you if you need to wait to start ENSPRYNG if your liver enzymes are increased.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Study 1: ENSPRYNG vs placebo

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

ENSPRYNG met the main study goal by reducing the risk of relapse and resulted in more AQP4-IgG(+) adult patients who were relapse-free at 96 weeks.

IN ADULT AQP4-IgG(+) PATIENTS ON ENSPRYNG

ENSPRYNG significantly reduced the risk of relapse by 74% vs placebo

More patients were relapse-free at 96 weeks with ENSPRYNG vs placebo

77% OF AQP4-IgG(+) PATIENTS ON ENSPRYNG

41% OF AQP4-IgG(+) PATIENTS ON PLACEBO

Important Safety Information

- **Low neutrophil count.**
  ENSPRYNG can cause a decrease in your neutrophil counts in your blood. Neutrophils are white blood cells that help the body fight off bacterial infections. Your healthcare provider should order blood tests to check your neutrophil count while you are taking ENSPRYNG.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Study 2: ENSPRYNG + immunosuppressive therapy (IST) vs placebo + immunosuppressive therapy (IST)

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

Overview of Study 2



Important Safety Information

- **Serious allergic reactions**.
  Serious allergic reactions that may be life-threatening have happened with other medicines like ENSPRYNG. Tell your healthcare provider before taking your next dose if you had hives, rash, or flushing after your injection. Seek medical attention right away if you have any symptoms of a serious allergic reaction, such as:

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Study 2: ENSPRYNG + immunosuppressive therapy (IST) vs placebo + immunosuppressive therapy (IST)

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

ENSPRYNG met the main study goal by reducing the risk of relapse and resulted in more AQP4-IgG(+) adult patients who were relapse-free at 96 weeks.

IN ADULT AQP4-IgG(+) PATIENTS ON ENSPRYNG PLUS IST

ENSPRYNG significantly reduced the risk of relapse by 78% vs placebo

More patients were relapse-free at 96 weeks with ENSPRYNG vs placebo + IST

91% OF AQP4-IgG(+) PATIENTS ON ENSPRYNG PLUS IST

57% OF AQP4-IgG(+) PATIENTS ON PLACEBO PLUS IST

Important Safety Information

- shortness of breath or trouble breathing
- dizziness or feeling faint
- swelling of your lips, face, or tongue
- moderate or severe stomach (abdominal) pain or vomiting
- chest pain

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Taking ENSPRYNG

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

Taking ENSPRYNG

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

ENSPRYNG treatment can be self-administered

ENSPRYNG is intended for home use or elsewhere, under the guidance of a healthcare provider (HCP). After proper training in subcutaneous injection technique, an adult patient or caregiver may self-inject ENSPRYNG, if your HCP determines that it is appropriate. There are resources you can use to understand how to properly administer ENSPRYNG.





Important Safety Information

Before you take ENSPRYNG, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection. See "What is the most important information I should know about ENSPRYNG?"
- have liver problems.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Taking ENSPRYNG

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

ENSPRYNG Dosing

During the first 4 weeks, you will have 3 starting doses (injections) of ENSPRYNG. You will receive 1 prefilled syringe (120 mg of ENSPRYNG) 2 weeks apart for each dose. After the starting doses, ongoing doses will be taken every 4 weeks.

If you miss a dose of ENSPRYNG, talk to your healthcare provider about restarting dosing.



Important Safety Information

- have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have had or have been in contact with someone with tuberculosis.
- have had a recent vaccination or are scheduled to receive any vaccination.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Administration | Storage & Handling

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

How to store and handle ENSPRYNG



Refrigerate at 36°F to 46°F (2°C to 8°C) in original box, to protect from light



If necessary, unopened ENSPRYNG can be removed from and returned to the refrigerator prior to administration

Do not freeze.
Do not shake.

If stored at room temperature, the total combined time out of refrigeration should not exceed 8 days at a temperature that does not exceed 86°F (30°C)

Important Safety Information

- are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if ENSPRYNG will harm your unborn baby.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Patient Support

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

Patient Support

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

ENSPRYNG Support

ENSPRYNG ACCESS SOLUTIONS®* IS THE PLACE TO TURN FOR ANSWERS AND SUPPORT

We offer a number of support services, including:

- Patient Navigator, your personal guide throughout your treatment with ENSPRYNG
- Supplemental injection training and support
- Financial assistance to help with the cost of your ENSPRYNG

*You and your healthcare provider are responsible for completing and submitting all required paperwork to your health insurance plan. Genentech (and any partner brand) cannot guarantee your plan will cover any treatments.

Important Safety Information

- are breastfeeding or plan to breastfeed. It is not known if ENSPRYNG passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ENSPRYNG.

Tell your healthcare provider about all the medicines you are taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Patient Support

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

Your Patient Navigator:

- Works with your doctor's office and/or specialty pharmacy to help you get your medicine
- Explains how your insurance can cover your ENSPRYNG treatment
- Helps you find financial assistance options, enroll, and navigate the ENSPRYNG Co-pay Program, if you are eligible
- Is available to answer questions about ENSPRYNG
- Can teach you about ENSPRYNG supplemental injection training

Feel supported along your journey.

Reach out to a Patient Navigator at **844-NSPRYNG (844-677-7964).**

Important Safety Information

What are the most common side effects of ENSPRYNG?

The most common side effects of ENSPRYNG include:

- sore throat, runny nose (nasopharyngitis)
- rash
- fatigue
- extremity pain
- headache
- upper respiratory tract infection
- nausea
- inflammation of the stomach lining (gastritis)
- joint pain (arthralgia)

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Patient Support

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

HELP WITH THE COST OF YOUR MEDICINE

Genentech is committed to helping you get the ENSPRYNG your doctor prescribed. Your Patient Navigator can help you find assistance options so you can pay for ENSPRYNG:

- If you have a commercial insurance plan*, you may be able to use the ENSPRYNG Co-pay Program†
- If you have a commercial or public insurance plan (such as Medicare or Medicaid), you may be referred to an independent co-pay assistance foundation‡
- If you have no insurance coverage or you can't pay for your medicine, the Genentech Patient Foundation§ may be able to help

*Commercial insurance includes plans you get through your employer or through a Health Insurance Marketplace like HealthCare.gov.

†Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medications. Patient must be taking the Genentech medication for an FDA-approved indication. See full terms and conditions at enspryngcopay.com.

‡Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.

§If you have health insurance, you must have already tried other types of financial assistance. You also need to meet income requirements.
If you do not have insurance, or if your insurance does not cover your Genentech medicine, you must meet different income requirements.

Important Safety Information

These are not all the possible side effects of ENSPRYNG.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Patient Support

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

INJECTION TRAINING SUPPORT

ENSPRYNG Clinical Education Managers provide supplemental injection training to patients or caregivers to ensure they are prepared to administer ENSPRYNG. Clinical Education Managers do not inject patients with ENSPRYNG.

They can:

- Set up a free 1:1 virtual injection training visit
- Provide ongoing injection training support throughout your ENSPRYNG treatment journey

Call **844-NSPRYNG (844-677-7964)** or enroll online at **www.ENSPRYNG.com**

Important Safety Information

You may also report side effects to Genentech at 1-888-835-2555.

For more information, go to www.ENSPRYNG.com or call 1-844-NSPRYNG.

Please see additional Important Safety Information throughout and full Prescribing Information and Medication Guide.

Important Safety Information

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

What is ENSPRYNG?

ENSPRYNG is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. It is not known if ENSPRYNG is safe and effective in children.

Who should not receive ENSPRYNG?

Do not take ENSPRYNG if you:

- are allergic to ENSPRYNG or any of the ingredients in ENSPRYNG.
- have an active hepatitis B infection.
- have active or untreated inactive (latent) tuberculosis.

What is the most important information I should know about ENSPRYNG?

ENSPRYNG may cause serious side effects including:

- **Infections**. ENSPRYNG can increase your risk of serious infections some of which can be life-threatening. Talk to your healthcare provider if you are being treated for an infection or call them right away if you think you have signs of an infection, with or without a fever, such as:
  - chills, feeling tired, muscle aches, cough that will not go away or a sore throat
  - skin redness, swelling, tenderness, pain or sores on your body
  - diarrhea, belly pain, or feeling sick
  - burning when you urinate or urinating more often than usual

Important Safety Information

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take ENSPRYNG.

- Your healthcare provider should test you for hepatitis and tuberculosis (TB) before you start taking ENSPRYNG.
- All required vaccinations should be completed before starting ENSPRYNG. People using ENSPRYNG should not be given 'live' or 'live-attenuated' vaccines. 'Live' or 'live-attenuated' vaccines should be given at least 4 weeks before you start ENSPRYNG. Your healthcare provider may recommend that you get a 'non-live' (inactivated) vaccine, such as some of the seasonal flu vaccines. If you plan to get a 'non-live' (inactivated) vaccine it should be given, whenever possible, at least 2 weeks before you start ENSPRYNG.
- **Increased liver enzymes.**
  Your healthcare provider should order blood tests to check your liver enzymes before and while you are taking ENSPRYNG. Your healthcare provider will tell you how often you will need to have these blood tests. Make sure you get all of your follow-up blood tests as ordered by your healthcare provider. Your healthcare provider will tell you if you need to wait to start ENSPRYNG if your liver enzymes are increased.
- **Low neutrophil count.**
  ENSPRYNG can cause a decrease in your neutrophil counts in your blood. Neutrophils are white blood cells that help the body fight off bacterial infections. Your healthcare provider should order blood tests to check your neutrophil count while you are taking ENSPRYNG.

Important Safety Information

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

- **Serious allergic reactions.**
  Serious allergic reactions that may be life-threatening have happened with other medicines like ENSPRYNG. Tell your healthcare provider before taking your next dose if you had hives, rash, or flushing after your injection. Seek medical attention right away if you have any symptoms of a serious allergic reaction, such as:
  - shortness of breath or trouble breathing
  - dizziness or feeling faint
  - swelling of your lips, face, or tongue
  - moderate or severe stomach (abdominal) pain or vomiting
  - chest pain

Before you take ENSPRYNG, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection. See **"What is the most important information I should know about ENSPRYNG?"**
- have liver problems.
- have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have had or have been in contact with someone with tuberculosis.
- have had a recent vaccination or are scheduled to receive any vaccination.
- are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if ENSPRYNG will harm your unborn baby.

Important Safety Information

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL

- are breastfeeding or plan to breastfeed. It is not known if ENSPRYNG passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ENSPRYNG.

Tell your healthcare provider about all the medicines you are taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the most common side effects of ENSPRYNG?

The most common side effects of ENSPRYNG include:

- sore throat, runny nose (nasopharyngitis)
- rash
- fatigue
- extremity pain
- headache
- upper respiratory tract infection
- nausea
- inflammation of the stomach lining (gastritis)
- joint pain (arthralgia)

These are not all the possible side effects of ENSPRYNG.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

For more information, go to www.ENSPRYNG.com or call 1-844-NSPRYNG.

For additional safety information, please see the full Prescribing Information and Medication Guide.

Thank you

Manufactured by: Genentech, Inc. A Member of the Roche Group 1 DNA Way, South San Francisco, CA 94080-4990

M-US-00010200(v1.0) 3/21

ENSPRYNG™
satralizumab-mwge
subcutaneous injection 120 mg/mL